CytoMed Therapeutics Limited Ordinary Shares Cash Flow Conversion Efficiency
CytoMed Therapeutics Limited Ordinary Shares cash flow conversion efficiency. Based on the latest financial reports, CytoMed Therapeutics Limited Ordinary Shares (GDTC) has a cash flow conversion efficiency ratio of -0.299x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.05 Million) by net assets ($6.85 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of CytoMed Therapeutics Limited Ordinary Shares (2019–2025)
Cash flow conversion efficiency of CytoMed Therapeutics Limited Ordinary Shares from 2019 to 2025. This chart illustrates how CytoMed Therapeutics Limited Ordinary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data. View CytoMed Therapeutics Limited Ordinary Sh (GDTC) share price today for real-time trading data and today's change.
CytoMed Therapeutics Limited Ordinary Shares Cash Flow Conversion Ratio Explained
CytoMed Therapeutics Limited Ordinary Shares cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
CytoMed Therapeutics Limited Ordinary Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CytoMed Therapeutics Limited Ordinary Shares ranked by their cash flow conversion efficiency. Also see GDTC stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CoinSmart Financial Inc
NEO:SMRT
|
-0.279x |
|
ERG S.A.
WAR:ERG
|
0.048x |
|
BSA Ltd
AU:BSA
|
0.022x |
|
Titan Logix Corp.
V:TLA
|
-0.028x |
|
Platina Resources Ltd
AU:PGM
|
-0.008x |
|
Entero Therapeutics, Inc.
NASDAQ:ENTO
|
-0.010x |
|
DCI O.N.
F:DCIK
|
N/A |
|
Guardian Exploration Inc
V:GX
|
0.634x |
Annual Cash Flow Conversion Efficiency for CytoMed Therapeutics Limited Ordinary Shares (2019–2025)
The table below shows the annual cash flow conversion efficiency of CytoMed Therapeutics Limited Ordinary Shares from 2019 to 2025. Review CytoMed Therapeutics Limited Ordinary Sh (GDTC) financial flexibility to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $6.85 Million | $-3.70 Million | -0.539x | -80.04% |
| 2024-12-31 | $9.04 Million | $-2.71 Million | -0.300x | +4.59% |
| 2023-12-31 | $11.27 Million | $-3.54 Million | -0.314x | +86.83% |
| 2022-12-31 | $589.03K | $-1.40 Million | -2.385x | -260.85% |
| 2021-12-31 | $2.60 Million | $-1.72 Million | -0.661x | +65.61% |
| 2020-12-31 | $476.83K | $-916.39K | -1.922x | -480.90% |
| 2019-12-31 | $1.94 Million | $-640.52K | -0.331x | -- |
About CytoMed Therapeutics Limited Ordinary Shares
CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I… Read more